{"schema_version":"secwatch.filing_event.v1","accession":"0001689548-23-000084","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.050697+00:00","generated_at":"2026-06-15T04:20:28.902571+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Praxis reports Q1 net loss $37.5M; PRAX-628 Phase 1 positive, cash runway into Q2 2024","bullets":["Q1 net loss $37.5M ($0.65 per share); cash & investments $85.8M as of March 31, 2023, funding operations into Q2 2024.","PRAX-628 Phase 1 well-tolerated; PK supports once-daily dosing; concentrations >15-fold MES EC50, indicating potential best-in-class efficacy for focal epilepsy.","Ulixacaltamide End-of-Phase 2 FDA meeting scheduled June 2023; Phase 3 program in essential tremor planned for H2 2023.","PRAX-562 EMBOLD study topline results expected Q4 2023; PRAX-222 EMBRAVE topline results expected H2 2023.","R&D expenses decreased to $25.5M from $52.7M YoY; G&A expenses decreased to $13.3M from $16.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-23-000084","json":"https://secwatch.observer/filing/0001689548-23-000084.json","markdown":"https://secwatch.observer/filing/0001689548-23-000084.md","text":"https://secwatch.observer/filing/0001689548-23-000084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954823000084/0001689548-23-000084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954823000084/prax-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:20:28.902571+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09c22071ef605405cf2e7624bcc416af31eb7579","claim":"Praxis Precision Medicines, Inc. reported the three months ended March 31, 2023 results: revenue $0.7 million.","evidence_excerpt":"Praxis recognized $0.7 million in collaboration revenue during the three months ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954823000084/0001689548-23-000084-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Revenue","value":"$0.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}